A high response rate to liposomal doxorubicin is seen among women with BRCA mutations treated for recurrent epithelial ovarian cancer
Sarah F. Adams, Evelyn B. Marsh, Wafic Elmasri, Steffanie Halberstadt, Stephanie VanDecker, Mary D. Sammel, Angela R. Bradbury, Mary Daly, Beth Karlan, Stephen C. RubinVolume:
123
Year:
2011
Language:
english
Pages:
6
DOI:
10.1016/j.ygyno.2011.08.032
File:
PDF, 412 KB
english, 2011